Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-3467
Abstract: Abstract Purpose: To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with IDH1/2-mutant (mut) acute myeloid leukemia (AML). Patients and Methods: Data were pooled from patients enrolled in a phase III study… read more here.
Keywords: patients idh1; treatment patients; risk; venetoclax azacitidine ... See more keywords
Safety and Efficacy of Ivosidenib Based Regimen in Patients with IDH1 Mutanted Acute Myeloid Leukemia: A Retrospective Case Series
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-207516
Abstract: Patients with IDH1-mutated acute myeloid leukemia (AML) are associated with poor prognosis, and the administration of IDH1 inhibitors show the significant therapeutic effect in such patients. Due to the low frequency of IDH1 mutations and… read more here.
Keywords: therapy; patients idh1; idh1; patient ... See more keywords
Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced solid tumors from a phase 1 study.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.2577
Abstract: 2577Background: Mutant isocitrate dehydrogenase 1 (mIDH1) produces the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib (IVO; AG-120) is a targeted mIDH1 inhibitor under evaluation in an ongo... read more here.
Keywords: pharmacodynamics ivosidenib; ivosidenib patients; patients idh1; mutant advanced ... See more keywords
Clinical pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies from a phase 1 study.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.2581
Abstract: 2581Background: Mutant isocitrate dehydrogenase 1 (mIDH1) produces the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib (IVO) is a selective mIDH1 inhibitor under evaluation in patients with ... read more here.
Keywords: clinical pharmacokinetics; pharmacodynamics ivosidenib; patients idh1; idh1 mutant ... See more keywords